ABSTRACT
In patients with active relapsing remitting multiple sclerosis (RRMS) and recent new-disease activity despite prior disease modifying therapy (DMT), hematopoietic stem cell transplantation (HSCT) halts disease progression, improves neurologic disability, improves quality of life, and provides a drug-free prolonged remission in a majority of patients that lasts for more than 5 years.
